The Use PUL-042 to Reduce the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2
Status:
Completed
Trial end date:
2021-07-31
Target enrollment:
Participant gender:
Summary
Subjects who have documented exposure to SARS-CoV-2 (COVID-19) will receive 4 doses of
PUL-042 Inhalation Solution or 4 doses of a placebo solution by inhalation over 10 days.
Subjects will be followed for the incidence and severity of COVID-19 over 28 days. Subjects
will be tested for infection with SARS-CoV-2 at the beginning, middle and end of the study.
Phase:
Phase 2
Details
Lead Sponsor:
Pulmotect, Inc.
Collaborator:
United States Department of Defense
Treatments:
Pam2CSK4 acetate and ODN M362 combination Pharmaceutical Solutions PUL-042